Treatment | Day of treatment or re-infestation | ||||||
---|---|---|---|---|---|---|---|
0 | 7 | 14 | 21 | 28 | 35 | ||
Placebo | Range | 4–21 | 12–32 | 6–26 | 11–34 | 13–36 | 5–22 |
A. mean | 11.6 | 21.9 | 19.1 | 20.1 | 26.3 | 16.5 | |
G. mean2 | 10.5a | 20.8a | 17.7a | 18.9a | 24.9a | 15.0a | |
Sarolaner | Range | 5–16 | 14–24 | 8–20 | 11–22 | 8–34 | 9–27 |
A. mean | 9.3 | 19.5 | 13.0 | 16.5 | 17.5 | 17.3 | |
Efficacy (%) | 20.4 | 10.9 | 32.0 | 18.0 | 33.3 | 0.0 | |
G. mean2 | 8.7a | 19.1a | 12.5a | 16.0a | 15.9a | 16.3a | |
Efficacy (%) | 16.8 | 8.4 | 29.5 | 15.5 | 36.0 | 0.0 | |
P-value vs. placebo | 0.4573 | 0.7074 | 0.1450 | 0.4773 | 0.0595 | 0.7298 | |
Afoxolaner | Range | 5–22 | 8–28 | 5–21 | 6–28 | 8–41 | 12–26 |
A. mean | 14.7 | 19.3 | 12.8 | 17.3 | 22.0 | 18.2 | |
Efficacy (%) | 0.0 | 11.6 | 32.9 | 13.9 | 16.2 | 0.0 | |
G. mean2 | 13.0a | 17.9a | 11.4a | 15.1a | 19.0a | 17.2a | |
Efficacy (%) | 0.0 | 14.3 | 35.5 | 20.1 | 23.7 | 0.0 | |
P-value vs. placebo | 0.4465 | 0.5668 | 0.1130 | 0.4092 | 0.3137 | 0.6098 | |
P-value vs. sarolaner | 0.2185 | 0.8293 | 0.7795 | 0.8560 | 0.5722 | 0.8543 |